All News

Oxy-Powder is designed to clean the digestive tract and oxidize and decrease the amount of impacted fecal matter.

National Asthma and Allergy Awareness Month highlights how pharmacists in all health care settings are in a unique position to improve management and outcomes of individuals with these conditions.

Imposter syndrome is a phenomenon that affects self-confidence, significantly limiting the effectiveness of professionals affected by it.

Analysis shows that half of individuals with both these sensory losses are cognitively impaired, investigators say.

Results from the DELIVER and DAPA-HF phase 3 trials demonstrate AstraZeneca’s Farxiga’s efficacy in heart failure, regardless of ejection fraction.

An international phase 1/2 clinical trial is ongoing for the treatment for individuals with relapsed or refectory acute myeloid leukemia with FLT3 mutation.

First phase 3 trial in this setting shows improved overall survival rates with an immunotherapy added to chemotherapy over the standard-of-care chemotherapy alone, company says.

Individuals who are not vaccinated with pre-existing diabetes, heart artery disease, or high blood pressure had a 2- to 3-fold increased risk of death, investigators say.

In an interview with Pharmacy Times, Amy Pfeifer, PharmD, BCPS, CSP, of AllianceRx Walgreens Prime, discussed the important role that pharmacists can play in the treatment of prostate cancer.

Jelmyto is an alkylating drug indicated for the treatment of adult patients with low-grade upper tract urothelial cancer.

Kank-A Mouth Pain Liquid is for the treatment of canker sore pain and other abrasions inside the mouth.

Spending 1 hour less sitting a day and increasing light physical activity helps prevent diseases, investigators find.

Individuals with college debt have a higher risk of cardiovascular illness, undermining the typical benefits of a post-secondary education, data indicate.

Mavacamten is a first-in-class selective allosteric modulator of beta cardiac myosin ATPase for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

The growth of telehealth during the COVID-19 pandemic has caused health care providers to search for innovative solutions for harder to reach patient populations.

Statistics indicate possible benefit of home-based palliative care interventions, according to study results from the Indiana University School of Medicine and the Regenstrief Institute.

Tea contains flavonoids, which are naturally occurring compounds that have antioxidant properties and provide bioactive compounds that help to neutralize free radicals.

Findings show that key factors include age, infecting variant, underlying illnesses, and vaccination status.

Palbociclib is indicated for adults in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men.

The drug combination achieved a median overall survival of more than 5 1/2 years in the first-line setting for postmenopausal women with HR+/HER2- aBC1, the company says.

Owning your time and scheduling self check-ins can help students avoid burnout.

FDA action was based on an analysis for the risk of thrombosis with thrombocytopenia syndrome, a rare and potentially life-threatening condition that causes blood clots combined with low levels of blood platelets.

Obinutuzumab is a CD20-directed cytolytic antibody used to treat certain types of blood cancer.

Relief Factor is a supplement that seeks to help users reduce body pains associated with daily living, aging, and exercise.

High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.

Even before the COVID-19 pandemic, vaccine hesitancy has been a challenge among adult patient populations.

Analysis results show taking iscosapent ethyl reduces the potential for CV death, coronary revascularization, hospitalization for unstable angina, myocardial infarction, and stroke by 35%.

The companies expect to complete the submission to the FDA for MDD in the first half of 2022 and an associated filing for postpartum depression in 2023.